Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)’s stock price has dropped by -0.97 in relation to previous closing price of 1007.96. Nevertheless, the company has seen a loss of -0.08% in its stock price over the last five trading days. benzinga.com reported 2024-10-11 that The stock market’s impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.
Is It Worth Investing in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Right Now?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has a higher price-to-earnings ratio of 26.44x compared to its average ratio, The 36-month beta value for REGN is at 0.11. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 12 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for REGN is 106.30M, and currently, shorts hold a 1.63% of that float. The average trading volume for REGN on October 18, 2024 was 538.73K shares.
REGN’s Market Performance
REGN stock saw a decrease of -0.08% in the past week, with a monthly decline of -12.34% and a quarterly a decrease of -6.15%. The volatility ratio for the week is 1.69%, and the volatility levels for the last 30 days are 2.40% for Regeneron Pharmaceuticals, Inc. (REGN). The simple moving average for the last 20 days is -3.21% for REGN’s stock, with a simple moving average of -1.45% for the last 200 days.
Analysts’ Opinion of REGN
Many brokerage firms have already submitted their reports for REGN stocks, with Leerink Partners repeating the rating for REGN by listing it as a “Market Perform.” The predicted price for REGN in the upcoming period, according to Leerink Partners is $1077 based on the research report published on September 24, 2024 of the current year 2024.
Bernstein, on the other hand, stated in their research note that they expect to see REGN reach a price target of $1125. The rating they have provided for REGN stocks is “Outperform” according to the report published on March 12th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to REGN, setting the target price at $1076 in the report published on January 12th of the current year.
REGN Trading at -10.15% from the 50-Day Moving Average
After a stumble in the market that brought REGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.58% of loss for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 1.69%, as shares sank -13.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.52% lower at present.
During the last 5 trading sessions, REGN fell by -0.08%, which changed the moving average for the period of 200-days by +10.30% in comparison to the 20-day moving average, which settled at $1,031.39. In addition, Regeneron Pharmaceuticals, Inc. saw 13.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REGN starting from RYAN ARTHUR F, who sale 100 shares at the price of $1048.78 back on Oct 01 ’24. After this action, RYAN ARTHUR F now owns 17,582 shares of Regeneron Pharmaceuticals, Inc., valued at $104,878 using the latest closing price.
McCourt Marion, the EVP Commercial of Regeneron Pharmaceuticals, Inc., sale 1,000 shares at $1054.06 during a trade that took place back on Oct 01 ’24, which means that McCourt Marion is holding 12,931 shares at $1,054,060 based on the most recent closing price.
Stock Fundamentals for REGN
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.86 for the gross margin
The net margin for Regeneron Pharmaceuticals, Inc. stands at 0.32. The total capital return value is set at 0.12. Equity return is now at value 16.55, with 12.95 for asset returns.
Based on Regeneron Pharmaceuticals, Inc. (REGN), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 2.05. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 125.35.
Currently, EBITDA for the company is 5.13 billion with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 8.08. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.44.
Conclusion
In conclusion, Regeneron Pharmaceuticals, Inc. (REGN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
